COVID-19

Dozens of presentations at IDWeek 2024 focused on available immunizations, such as those for COVID-19, respiratory syncytial virus, and flu.

A study published in Arteriosclerosis, Thrombosis, and Vascular Biology found the risk of major adverse cardiac events was higher in patients hospitalized with COVID-19.

Additional research is needed to determine if the therapy can help with cognitive symptoms of post–COVID-19 condition.

The COVID-19 pandemic negatively impacted mental health in young people, and additional targeted mental health resources are needed.

Research presented at CHEST 2024 examined outcomes of COVID-19 on patients with alcoholic liver disease, cirrhosis, and non-alcohol steatohepatitis.

The Healgen Rapid Check COVID-19/Flu A&B Antigen Test is the first at-home test to be granted marketing authorization using a traditional premarket review pathway.

Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.

Research being presented at CHEST 2024 analyzed morbidity and outcomes of children infected with influenza, COVID-19 or both.

Data from the SELECT clinical trial were analyzed to evaluate the role of semaglutide therapy on all-cause, cardiovascular, and non-cardiovascular mortality during the COVID-19 pandemic.

Bezisterim acts on inflammatory signaling pathways and may be a viable treatment option for post–COVID-19 condition, or long COVID.

The protein-based vaccine includes a monovalent component corresponding to the Omicron variant JN.1 strain.

Chijioke Bennett, executive director of clinical development at Novavax, discusses how health care providers can increase awareness around the importance of COVID-19 vaccines.

Chijioke Bennett, executive director of clinical development at Novavax, discusses how health care providers can increase awareness around COVID-19 vaccination and how to help patients overcome vaccine hesitancy.

Researchers addressed the association of COVID-19 pandemic-related school disruptions with children’s incidence of acute psychiatric emergencies.

The government said the tests will “detect current COVID-19 variants and can be used through the end of the year.”

Novavax is still awaiting FDA authorization for their protein-based COVID-19 vaccine.

Experts analyzed data from the National Center for Health Statistics on the leading causes of death in the US from the last 5 years.

The composition of the latest flu vaccine has changed. Here’s what pharmacists need to know.

Researchers aimed to address the change in trust individuals exhibited regarding US physicians and hospitals during the COVID-19 pandemic.

Recent research on COVID-19 examined cognitive loss after an infection, how pandemic restrictions impacted excess deaths, and the increase in physicians experiencing PTSD.

“If people think COVID is no big deal and decide to forgo vaccinations, they’re essentially doubling their risk of developing long COVID,” wrote investigators.

COVID-19 patients had reduced absolute granulocyte, monocyte, and lymphocyte counts at 10 months post-infection compared to noninfected individuals.

Updated vaccines are expected to be available in the coming months.

The updates follow the Advisory Committee for Immunization Practice meeting held June 26 to 28, 2024.

Test your pharmacy news knowledge with our weekly quiz.